

ORAL PRESENTATIONS

Preclinical	Title	Presenter
OP-001	Ga68-labeled compounds for infection imaging	Thomas Ebenhan, Pelindaba, South Africa. Email: ebenhan@gmail.com
OP-002	New NOTA based bisphosphonates for diagnosis of bone metastases.	Marian Meckel, Mainz, Germany. Email: meckelm@uni-mainz.de
OP-003	Synthesis and Biological Evaluation of ⁶⁸ Ga(Chal) ₂ DT as PET Agent for A β Plaques in Brain.	Kanchan Chauhan, Delhi, India. Email: chauhankanchan4@gmail.com
OP-004	Evaluation of Gallium-68 Phosphonate Complexes for Bone Imaging Using MicroPET.	Ambika Parmar Delhi, India. Email: akmishra63@gmail.com
OP-005	⁶⁸ Ga-Alpha-Fetoprotein Peptide Fragment for Tumor Imaging	A.A. Larenkov, Moscow, Russia. Email: anton.larenkov@gmail.com
OP-006	Synthesis, characterization and radiolabeling of DTPA-doxorubicin complex with ⁶⁸ Ga as potential PET tumor imaging agent- A PRECLINICAL Evaluation.	Pardeep Kumar, Chandigarh, India Email: pktpgi@yahoo.com

Clinical	Title	Presenter
OP-007	Gallium-68 compounds partly replace- ¹⁸ F-FDG in PET molecular imaging.	Kiran T, Bengaluru, India. Email: mrtkiran@gmail.com
OP-008	Detection of prostate cancer with the [⁶⁸ Ga]-labeled bombesin antagonist RM2 in patients undergoing radical prostatectomy.	Andre Mueller, Berlin, Germany. Email: andre.mueller@piramal.com
OP-009	Feasibility of Y-90 PET-CT following Radioembolization.	Senthil R, Chennai, India. Email: senthilrajapgi@yahoo.com
OP-010	Theranostics of Neuroendocrine Neoplasms: Molecular Response and Prognosis Assessment after Peptide Receptor Radionuclide Therapy using Ga-68 Somatostatin Receptor PET/CT.	Harshad R. Kulkarni, Bad Berka, Germany. Email: harshad.kulkarni@zentraklinik.de
OP-011	The Usage of deformable phantoms for Personalized Dosimetry in Radionuclide Therapy.	Matthias Blaickner, Bad Berka, Germany. Email: matthias.blaickner@ait.ac.at
OP-012	Guidelines for Safe, Effective Outpatient Lutetium-177 Octreotate Radiopeptide Therapy for Neuroendocrine Tumours and minimisation of Radiation Exposure of Carers, Hospital Staff and General Public.	Phillipe J. Calais, Australia Email: phillip.calais@health.wa.gov.au

Therapy	Title	Presenter
OP-013	²²⁵ Ac and ²¹³ Bi α -particle-emitter therapy in combination with SAHA and 17-AAG.	Srinivasan Senthamizhchelvan, Karlsruhe, Germany. Email : ssrniv9@jhmi.edu
OP-014	Preparation and Preliminary Studies on ¹⁷⁷ Lu-Labeled RGD : Peptide Derivative for Targeted Tumor Therapy	Sudipta Chakraborty, Mumbai, India. Email: sudipta@barc.gov.in
OP-015	Nano-carriers: A Better Alternative to Amino Acid Co-Infusion in PRRNT for Renal Protection.	Geetanjali Arora, Delhi, India. Email: a.geetanjali@gmail.com
OP-016	Whether PRRT Connecting with Long Acting Somatostatin Analogue may Lengthen Survival in Group of Patients with NET?	Anna Sowa-Staszczak, Poland. Email : sowiana@gmail.com
OP-017	A DOTA-Analog Phosphinate Chelator for Application in Multimeric Bioconjugates and Theranostics.	Johannes Notni, Germany. Email: johannes.notni@tum.de
OP-018	Addition of erythropoietin is effective in stabilizing haemoglobin in patients with pre-existing grade-3 cancer induced anaemia needing radionuclide therapy for bone pain palliation.	Sukanta Barai, Lucknow, India. Email: danzig@rediffmail.com

Radio-pharmacy	Title	Presenter
OP-019	The NaCl based ⁶⁸ Ga labeling procedure – a suitable method for research and clinical applications.	Dirk Mueller, Bad Berka, Germany. Email: dirk.mueller@zentalklinik.de
OP-020	⁶⁸ Ga-DOTA-Substance-P as a Tool for Diagnostics and Locoregional Administration Follow up of ²¹³ Bi-DOTA-Substance-Pin the Course of Glioma Therapy.	Dariusz Pawlak, Warsaw, Poland. Email: d.pawlak@polatom.pl
OP-021	Development of Ga-68 Labeled Novel Peptide Based Imaging Agent for Neoplastic Lesions and Solid Tumors.	Harleen Khurana, Delhi, India. Email: akmishra63@gmail.com
OP-022	From Bench to Bedside with ⁶⁸ Ga-TRAP Radiopharmaceuticals: Synthesis, characterization, and Clinical Application of [⁶⁸ Ga]TRAP(RGD) ₃ .	Johannes Notni, Germany Email: johannes.notni@tum.de
OP-023	LAT1 Uptake of Methionine Based Imaging Probe labeled with 68Gallium for the visualization of Gliomas in vivo by PET.	Puja P. Hazari Delhi, India. Email: puja_panwar@yahoo.com
OP-024	Equilibrium, Kinetic and Structural Studies of Gallium(III)-Complexes Formed with AAZTA Ligand.	Zsolt Baranyai, Hungary. Email: mczsozso@yahoo.co.uk

POSTER PRESENTATIONS

Preclinical	Title	Presenter
P-025	Evaluation of ^{68}Ga -DTPA-bis(INH) Conjugate in Early Detection of Infection in Animal Model Using Animal PET System.	Ankur Kaul, Delhi, India. Email: akmishra63@gmail.com
P-026	Biodistribution of a ^{68}Ga -DOTA-USPIO in normal Balb/c mice.	Saeed Shanehsazzadeh, Sydney, Australia. Email : sa27sh@gmail.com
P-027	Synthesis of Bis Macrocyclic Chelate (^{68}Ga -DO3P-AME-DO3P): Preclinical Evaluation as PET Agent for Diagnosis of Skeletal Metastases.	K Ganesh Kadiyala, Delhi, India. Email: kganeshkadiyala@gmail.com
P-028	PET Imaging of Ga-68 Labelled Dual-Targeted Domain Antibody TM Therapeutics in a Cancer Model.	Alex G. Papple, London. Email : a.g.papple@qmul.ac.uk
P-029	^{68}Ga -labelled Cetuximab using Cysteine based DTPA NCS for Immuno-PET Imaging of Colorectal Cancer.	Jae Cheong Lim, Korea. Email: limjc@kaeri.re.kr
P-030	Radioimmuno Imaging of a ^{68}Ga -DOTA-MSH Derivative Analogue for Melanocortin-1 Receptor Positive Tumor Targeting.	Joh Eun-Ha, Korea. Email: choeh36@kaeri.re.kr
P-031	Facile DOTA-Conjugation and Radiolabeling of Cysteine-Knot Peptides with Ga-68 and Lu-177 as a Promising <i>Theranostic</i> Tool.	Benedikt Sandhöfer, Mainz, Germany Email: sandhoef@uni-mainz.de
P-032	Indigenous development of a single vial kit preparation of $^{99\text{m}}\text{Tc}$ -doxorubicin and its Preclinical evaluation for tumor imaging.	Pardeep Kumar, Chandigarh, India. Email: pktptgi@yahoo.com
P-033	Preclinical evaluation of $^{99\text{m}}\text{Tc}$ labeled gefitinib as a tumor imaging.	Shalini Chopra, Chandigarh, India. Email: sheli_chopra@yahoo.co.in
CLINICAL		
P-034	Response evaluation in Non Small Cell Lung Carcinoma (NSCLC) of EGFR inhibitor therapy by ^{18}F -FLT and ^{18}F -FDG PET/CT - A comparative study.	Amit Bhoil, Chandigarh, India. Email: amitbhoil@yahoo.com
P-035	^{18}F FDOPA: A superior PET-tracer for the accurate diagnosis of neuroendocrine tumours and a possible alternative to ^{68}Ga -PET tracers.	Raman Chirakal, Canada. Email: chiraklr@mcmaster.ca
P-036	^{18}F -FDG Labelled Stem Cells Localisation in Type 2 Diabetes Mellitus by PET/CT for Defining Adequate Administration Routes.	Vikas Sood, Chandigarh, India. Email: vikasvineeta@rediffmail.com
P-037	Evaluation of Patients with	Omar Alonso, Uruguay.

	Neuroendocrine Metastatic Carcinoma of Unknown Primary by Means of Ga-68 DOTATATE PET-CT.	Email: alonso.om@gmail.com
P-038	Comparison of Ga-68 DOTATATE and C-11 CHOLINE Uptake in Patients with Castration Resistant Prostate Cancer.	Omar Alonso, Uruguay. Email: alonso.om@gmail.com
P-039	Skin Manifestations Associated with Neuroendocrine Tumors.	Jolanta Kunikowska, Poland. Email: jolanta.kunikowska@wum.edu.pl
P-040	To evaluate the diagnostic efficacy of ^{99m} Tc-DTPA-bis-methionine for the detection of primary lesions in breast cancer & gliomas patients: preliminary results.	Himani Verma, Chandigarh, India. Email: pktpgi@yahoo.com
P-041	Heterogeneous Regional Physiological Uptake of 18F-FDG in Myocardium in Fasting Oncologic Patients on Whole Body PET-CT Scans.	Anna Ara Khan, Chandigarh, India. Email: khan.anna11@yahoo.com
P-042	Evaluation of Tumor Response after Radiofrequency Ablation of Hepatic Metastases from Neuroendocrine Neoplasms using Ga-68 Somatostatin-Receptor PET/CT.	Harshad R. Kulkarni, Bad Berka, Germany. Email: harshad.kulkarni@zentalklinik.de
DOSIMETRY		
P-043	Estimation of Human Effective Absorbed Dose of ⁶⁸ Ga-DTPA-GONADORELIN Based on Biodistribution Rat Data.	Afsaneh Lahooti, Tehran, Iran. Email: afsanehlahooti@gmail.com
P-044	Repeated Cycles of Peptide Receptor Radionuclide Therapy: Is it Safe for the Kidneys and What is the Effect of Cumulative Mean Absorbed Renal Dose?	Harshad R. Kulkarni, Bad Berka, Germany. Email: harshad.kulkarni@zentalklinik.de
P-045	Biodistribution and Dosimetry of ¹³¹ I-Rituximab Radioimmunotherapy in Non- Hodgkin's B-Cell Lymphoma: Preliminary Experience from Ramathibodi Hospital, Thailand.	Wirote Changmuang, Bangkok, Thailand. Email: wirochana@yahoo.com
THERAPY		
P-046	Evaluation of Feasibility of PRRT in Neuroblastoma Using ^{99m} Tc- Hynic-TOC Scintigraphy.	V.Rangarajan, Mumbai, India. Email : drvrangarajan@gmail.com
P-047	Lutetium Therapy in Metastatic Pheochromocytoma.	Manoj K Bhatt, Herston, QLD, Australia 4029. Email : drmkbhatt@yahoo.co.uk

P-048	Project for Cyclotron Production of Ac-225 in Tomsk Polytechnic University.	Vladimir M.Golovkov, Tomsk, Russia. Email : golovkov@tpu.ru
P-049	⁶⁴ Cu-Asparagine: Glioblastoma Treatment.	Gianluca Valentini, Montecosaro, Italy. Email : g.valentini@acompet.it
P-050	90Y sphere Radioembolization and associated Infectious complications.	Sandeep Laroia, Iowa, USA. Email: sandeep-laroia@uiowa.edu
RADIOPHARMACY		
P-051	Evaluation of a new ⁶⁸ Ge/ ⁶⁸ Ga generator designed by Nordion for labelling of PET imaging radiopharmaceuticals.	Damien Cressier, France. Email: cressier@cyceron.fr
P-052	Quantitative determination of ⁶⁸ Ge breakthrough of ⁶⁸ Ge/ ⁶⁸ Ga generators via TLC.	Elisabeth Eppard, Mainz, Germany. Email: eppard@uni/mainz.de
P-053	Development of an ethanol-based post-processing for generator-produced ⁶⁸ Ga for medical application.	Elisabeth Eppard, Mainz, Germany. Email:eppard@uni/mainz.de
P-054	Improved efficacy of synthesis of ⁶⁸ Ga and other M(III)-labeled radiopharmaceuticals in mixtures of aqueous solution and non-aqueous solvents.	Frank Rösch Habana, Cuba. Email: froesch@uni-mainz.de
P-055	Purification of Ga-68 eluate using ion exchange and solvent extraction methods: Comparisons of the qualities of the purified Ga-68 eluate.	Malay Kanti Das Kolkata, India. Email: mkdas@vecc.gov.in
P-056	Quick, cost effective and reliable synthesis of Ga-68 DOTATE using manual Synthesis module.	Nitasha, Chandigarh, India. Email: nitashagarg89@yahoo.com
P-057	In Vivo and in Vitro Assay of the Small Labelled Peptide in Nuclear Medicine.	Parviz Ashtari, Karaj, Iran. Email: pashtari@nrcam.org
P-058	NODAGA and DOTA-Flurpiridaz derivatives for Myocardial Perfusion Imaging with ⁶⁸ Ga.	Verena Nagel, Mainz, Germany. Email : nagelv@uni-mainz.de
P-059	<i>In vivo</i> PET Screening of Different ⁶⁸ Ga Schiff Base Amines for Myocardial Imaging.	Melanie Zimny, Mainz, Germany Email: zimny@uni-mainz.de
P-060	⁶⁸ Ga-Deferoxamine-Cysteine, a potential radiopharmaceutical for Tumor Imaging.	Virendra K. Meena Delhi, India. Email: akmishra63@gmail.com
P-061	A Novel Bifunctional Macrocyclic chelator for improved labeling of	Surbhi Prakash Delhi, India.

	Biovectors with Gallium-68.	Email: akmishra63@gmail.com
P-062	Optimisation of Labelling Conditions for Bone Marrow Derived Stem Cells When Labelled with PET Tracer ¹⁸ F- FDG.	Vikas Sood, Chandigarh, India. Email: vikasvineeta@rediffmail.com
P-063	Molecular Imaging of Prostate Cancer Using a New ⁶⁸ Ga Labeled Peptide.	Anchal Ghai, Iowa, USA. Email: anchal-ghai@uiowa.edu
P-064	Synthesis of Generator Based ⁶⁸ Ga- Labeled DOTANOC by an Automated Module: 3 year Indian Experience.	Rajeev Kumar, Delhi, India Email: rajeevraj_aiims@yahoo.com
P-065	⁶⁸ Ga-Labeled Cyclic Phosphonates for PET Imaging of Skeletal Metastases: A Preliminary Investigation.	Sudipta Chakraborty, Mumbai, India. Email: sudipta@barc.gov.in
P-066	New Clickable Bifunctional Chelates for ⁶⁸ Ga and their Labeling Characteristics.	Johanna Seeman, Mainz, Germany. Email: johanna.seemann@uni-mainz.de
P-067	Application of Combined Cation-Anion Exchange Processes in Mixed Media for Preparation of High-Purified ⁶⁸ Ga Solutions: <i>Comparison of HCl-Acetone and HCl-Ethanol Media.</i>	A.A. Larenkov, Moscow, Russia. Email: anton.larenkov@gmail.com
P-068	Production of Ga ⁶⁸ DOTA-Peptide using Manual Labeling system & Ge ⁶⁸ /Ga ⁶⁸ Generator-ITG –Initial Indian Experience of 150 Runs.	Atul Gada, Hyderabad India. Email: atulgada@gmail.com
P-069	Chelators highly selective for Ga-68 and the practical consequences thereof.	Jakub Šimeček Munich, germany. Email: jakubsimecek@tum.de
P-070	Radiolabeling of DOTATATE with ⁶⁸ Ga Via Single Vial Kit Method Suitable with Commercial Generator.	Aruna Korde Mumbai, India. Email : akorde@barc.gov.in
P-071	Synthesis and Biological Evaluation of Macrocyclic DO3A-ATR- ⁶⁸ Ga: A Potential Probe for PET Imaging.	Anupriya Adhikari, Delhi, India. Email: anupriyaadhikari2@gmail.com
P-072	Aspects on the synthesis of ¹⁷⁷ Lu-DOTA-tate and C ₁₈ purification: re-addition of ascorbic acid is required to maintain radiochemical purity.	Stephan Maus Netherlands. Email : Stephan.Maus@Unimedizin-mainz.de
P-073	Evaluation of ⁶⁸ Ga-2-Methoxy phenylpiperazine(MPP) Derivatives Selective for Serotonin 5HT _{1A} for Neuroreceptor Imaging.	Puja P. Hazari Delhi, India. Email: puja_panwar@yahoo.com
P-074	Alternative Method to Determine Specific Activity of (n,γ) Reactor-	WAP Breeman Rotterdam, The Netherlands. Email:

	Produced ^{177}Lu from Enriched ^{176}Lu .	w.a.p.breeman@erasmusmc.nl
P-075	Detailed Evaluation on the Effect of Metal Ion Impurities on Generator Eluted Gallium-68 with Different Bifunctional Chelators.	Ashutosh Dash, Mumbai, INDIA. Email: adash@barc.gov.in
P-076	Many-Years Experience of Investigation, Production and Deliveries of Ga-68 Generators from Cyclotron, Obninsk.	A. Razbash Moscow, Russia. Email: gkodina@yandex.ru
P-077	Design and Development of DTPA-(Asn) ₂ Radiolabelled with ^{68}Ga For PET Imaging Application.	Vikas Kumar Delhi, INDIA. Email: vikas.gene@gmail.com
P-078	Synthesis and Radiolabeling of ^{68}Ga -Colchicine as a Potential Imaging Agent for Multidrug Resistance in Tumors.	Drishty Satpati Mumbai. Email: drishtys@barc.gov.in
P-079	Preparation and preliminary <i>in vitro</i> evaluation of ^{177}Lu -labeled Rituximab.	Tapas Das, Mumbai, India. Email: tdas@barc.gov.in
P-080	Development of Tridentate Acyclic Indole Derived System for Gallium PET Imaging Applications.	Swati Aggarwal, Delhi, India. Email: swats2201@gmail.com
P-081	Alternative Method of ^{68}Ga and ^{177}Lu Purification.	Van So Le, Australia. Email: vansole01@gmail.com
P-082	Synthesis and Evaluation of ^{68}Ga -Labeled EDTA Conjugated 2-Amino Pyridine Analogue as an Imaging Agent and its Interaction with Human Serum Albumin (HSA).	Pooja, Delhi, India. Email: pooja.chem123@gmail.com
P-083	Computational DFT Protocol Prediction of Fluorescence of Gallium Based Imaging Tracer.	Nidhi Chadha, Delhi, India. Email: chadha.nidhi3693@gmail.com
P-084	Kinetic Properties of the Gallium(III)-AAZTA Complexes Near to Physiological Conditions.	Imre Tóth Debrecen, Hungary. Email: imre.toth@science.unideb.hu
P-085	Design, Synthesis and Characterization of Methionine Conjugated Novel Tetraaza Bifunctional Chelating Agent and <i>in Vivo</i> and <i>in Vitro</i> Studies.	Neelam Yadav Delhi, India. Email: bsinghbhu@rediffmail.com
P-086	Design, Synthesis and Preclinical Evaluation of Ga(III)-DOTA-RGD-Ranatensin for Dual Integrin and GRPR-Targeted Tumor Imaging.	Raunak Varshey, Delhi, India. Email: raunak_varshney@yahoo.com
P-087	Design and Synthesis of Novel ^{68}Ga (III)-DOTA-Bismethoxyphenyl-piperazine derivative for D ₃ Receptor	R Sandhya, Delhi, India. Email:

	PET Imaging.	raunak_varshney@yahoo.com
P-088	⁶⁸ Ga-DOTA-bistriazole-bis-(1,3,8-triazaspiro[4,5]decan-4-one): A PET Radiopharmaceuticals for D ₂ Receptor Imaging.	Swarndeeep Kaur Sethi, Delhi, India. Email: raunak_varshney@yahoo.com
P-089	Our Experience with Gallium-68 Generators.	M.K. Srivastava, Chennai, India. Email: drmadhur77@yahoo.co.in
P-090	Evaluation of DO3MP-EA as Bifunctional Bone Imaging Agent for PET Application.	Pooja Srivastava Delhi, India Email: pshree_14@yahoo.co.in
P-091	Cationic Eluate Pre-treatment for automated synthesis of 68-Gallium labeled peptides.	Rene Martin, Radeberg, Germany. Email: rene.martin@abx.de
P-092	Comparative study using Acetone based and NaCl based methods in Eckert& Zeigler tubing system	H.H. Shimpi, Mumbai, India Email: shimpihh@yahoo.com
(Scintigraphy, Drug Development/Radiation biology & others)		
P-093	Radio-Labeling Strategies of Stem Cells.	Vikas Sood, Chandigarh, India. Email: vikasvineeta@rediffmail.com
P-094	Fourier Transform Infrared Spectroscopic Studies on Structural Organisation of DNA from Hepatic Cancer Cells and Modulatory Effects of AAILE.	Sanjay Bharati, Chandigarh, India. Email: yellowidme@gmail.com
P-095	Development, toxicity evaluation and pre-corneal retention behavior of a novel chelator based ophthalmic formulation using gamma scintigraphy.	Neeraj Kumar, Delhi, India. Email: assem_bhatnagar@indiatimes.com.
P-096	Fluticasone propionate nanoparticle dry powder inhalation: development, characterization and pharmacoscintigraphic evaluation.	Amit Kumar, Delhi, India. Email: assem_bhatnagar@indiatimes.com
P-097	Nano-alendronate dry powder inhalation: a novel approach for decorporation of inhaled heavy metals.	Gaurav Mittal, Delhi, India. Email: assem_bhatnagar@indiatimes.com
P-098	Efficacy evaluation of a few herbal agents for radioactivity decontamination of potable water using radiometry	Harish Rawat, Delhi, India. Email: assem_bhatnagar@indiatimes.com
P-099	Radiolabeling and biological evaluation of sildenafil citrate respiratory fluid as a potential treatment of pulmonary hypertension.	Thakuri Singh, Delhi, India. Email: assem_bhatnagar@indiatimes.com
P-100	Identification of novel non-invasive biochemical markers for acute radiation injury: a preliminary study.	Sandeep Soni, Delhi, India. Email:

		assem_bhatnagar@indiatimes.com
--	--	--------------------------------